Driving impactful narratives and strategic growth through innovative communication and marketing leadership.
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/8OuBjZ #cellandgenetherapies #CGT #advancedtherapies #raredisease
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/VXlq1J #cellandgenetherapies #CGT #advancedtherapies #raredisease
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/jU3zZs #cellandgenetherapies #CGT #advancedtherapies #raredisease
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/otKifp #cellandgenetherapies #CGT #advancedtherapies #raredisease
Business Development Director, Biologics Testing Solutions at Charles River Laboratories
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/r8fXWw #cellandgenetherapies #CGT #advancedtherapies #raredisease
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/wuSb1U #cellandgenetherapies #CGT #advancedtherapies #raredisease
Business Development Manager Central/South Spain Charles River Laboratories
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/0akMqB #cellandgenetherapies #CGT #advancedtherapies #raredisease
Business Development Manager, Gene Therapy CDMO Services - East @ Charles River Labs
With a staggering 7,000 rare diseases spanning various therapeutic areas, take a moment to discover the latest collaborations, frameworks, and portfolios designed to support drug development. Explore the extraordinary: https://okt.to/1e6Cl2 #cellandgenetherapies #CGT #advancedtherapies #raredisease #genetherapy
2025 promises to represent another rich year of progress. https://ow.ly/5JxC50TKMAf A wealth of new therapies are set to successfully graduate from the pipeline. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and, most importantly, treatments that will meaningfully change how diseases are treated. This article provides a snapshot of these advancements and the potential new approvals to add to your vocabulary, from apitegromab to Zegalogue. Click the link in this post to read the article.
2025 promises to represent another rich year of progress. https://ow.ly/5JxC50TKMAf A wealth of new therapies are set to successfully graduate from the pipeline. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and, most importantly, treatments that will meaningfully change how diseases are treated. This article provides a snapshot of these advancements and the potential new approvals to add to your vocabulary, from apitegromab to Zegalogue. Click the link in this post to read the article.
2025 promises to represent another rich year of progress. https://ow.ly/5JxC50TKMAf A wealth of new therapies are set to successfully graduate from the pipeline. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and, most importantly, treatments that will meaningfully change how diseases are treated. This article provides a snapshot of these advancements and the potential new approvals to add to your vocabulary, from apitegromab to Zegalogue. Click the link in this post to read the article.
